title: Lymphocyte-derived interleukin-17A adds another brick in the wall of inflammation-induced breast carcinogenesis.
abstract: We have previously reported that a subset of breast tumors are infiltrated with IL-17A-producing tumor-associated lymphocytes and that IL-17A cytokine is principally associated with estrogen receptor negative (ER-) and triple negative, basal-like tumors. We established that IL-17A producing lymphocytes induced cancer cell proliferation, chemoresistance, and invasion, indicating that IL-17A is a potential therapeutic target for breast malignancies.
authors: OREGA Biotech; Ecully, France.
authors: Jérémy
authors: J
authors: Bastid
authors: IRCM, Institut de Recherche en Cancérologie de Montpellier; INSERM, U896; Université Montpellier 1; CRLC Val d'Aurelle Paul Lamarque; Montpellier, France.
authors: Nathalie
authors: N
authors: Bonnefoy
authors: IRCM, Institut de Recherche en Cancérologie de Montpellier; INSERM, U896; Université Montpellier 1; CRLC Val d'Aurelle Paul Lamarque; Montpellier, France ; Département d'Immunologie; Centre Hospitalier Régional Universitaire de Montpellier et Faculté de Médecine Université Montpellier 1; Montpellier, France.
authors: Jean-François
authors: JF
authors: Eliaou
authors: Institut National de la Santé et de la Recherche Médicale (INSERM) UMR-S 976; Paris, France ; Université Paris Diderot; Sorbonne Paris Cité; Laboratoire Immunologie Dermatologie & Oncologie; Paris, France.
authors: Armand
authors: A
authors: Bensussan
keywords: ERK kinases; IL-17A; breast cancer; chemoresistance; monoclonal antibodies; tumor infiltrating lymphocytes